A5012125170- Cancer Mechanisms and Therapy
- Phagocytosis and Immune Regulation
- Pancreatic and Hepatic Oncology Research
- Impact of Technology on Adolescents
- Technology Adoption and User Behaviour
- Digital Mental Health Interventions
- Child and Adolescent Psychosocial and Emotional Development
- Digital Marketing and Social Media
- Cell Adhesion Molecules Research
- Diverse Educational Innovations Studies
- Glioma Diagnosis and Treatment
- RNA modifications and cancer
- Macrophage Migration Inhibitory Factor
- Peptidase Inhibition and Analysis
- IoT and Edge/Fog Computing
- Apelin-related biomedical research
- Nuclear Receptors and Signaling
- Educational Research and Pedagogy
- COVID-19 and Mental Health
- Education Systems and Policy
- Cancer Genomics and Diagnostics
- Green IT and Sustainability
- Mathematics Education and Programs
- Engineering Education and Pedagogy
- Interactive and Immersive Displays
Center for Clinical Research (United States)
2010-2023
Simon Fraser University
2022
University of Portsmouth
2022
The Ohio State University
2015
Ludwig Cancer Research
2014
Stanford University
2010
University of Illinois Urbana-Champaign
2010
Gynecologic Oncology Group
2010
The receptor tyrosine kinase AXL is thought to play a role in metastasis; however, the therapeutic efficacy of an AXL-targeting agent remains largely untested metastatic disease. In this study, we defined as target for ovarian cancer. primarily expressed metastases and advanced-stage human tumors but not normal epithelium. Genetic inhibition tumor cells sufficient prevent initiation disease vivo. Mechanistically, signaling animals with results decreased invasion matrix metalloproteinase...
Problem Despite the increasing prevalence of mental health disorders in university students, few receive needed evidence‐based treatment. Objective The purpose this study was to assess feasibility and preliminary effects a seven‐session online cognitive‐behavioral skill‐building intervention (i.e., COPE , Creating Opportunities for Personal Empowerment) versus comparison group on their anxiety, depressive symptoms, grade performance. Methods A randomized controlled pilot conducted from S...
Abstract EGFR is the most common genetically altered oncogene in glioblastoma (GBM), but small-molecule tyrosine kinase inhibitors (TKI) have failed to yield durable clinical benefit. Here, we show that two novel model systems of acquired resistance TKIs, elevated expression urokinase plasminogen activator (uPA) drives signaling through MAPK pathway, which results suppression proapoptotic BCL2-family member protein BIM (BCL2L11). In patient-derived GBM cells and genetic models, uPA shown...
<p class="first" id="d1020125e65">Technology is both a useful tool and source of frustration. Researchers product designers strive to predict meet user needs by studying intentions toward, experiences with, technology. Such work has focused primarily on improving the user’s device interactions improve usability, while (largely) ignoring effect that frustration with technology their psychological well-being. We performed questionnaire study (n=211) assess users’ feelings about different...
<div>Abstract<p>The receptor tyrosine kinase AXL is thought to play a role in metastasis; however, the therapeutic efficacy of an AXL-targeting agent remains largely untested metastatic disease. In this study, we defined as target for ovarian cancer. primarily expressed metastases and advanced-stage human tumors but not normal epithelium. Genetic inhibition tumor cells sufficient prevent initiation disease <i>in vivo</i>. Mechanistically, signaling animals with...
Supplementary Figure 9 from AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
Supplementary Methods, Figure Legends 1-9 from AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
Supplementary Figure 3 from AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
Supplementary Figure 6 from AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
Supplementary Figure 1 from AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
Supplementary Figure 8 from AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
Supplementary Figure 4 from AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
Supplementary Figure 5 from AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
Supplementary Figure 7 from AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
Supplementary Figure 2 from AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
Supplementary Methods, Figure Legends 1-9 from AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
Supplementary Figure 9 from AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
Supplementary Figure 2 from AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
Supplementary Figure 4 from AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer